Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

Delays seem like clear setbacks, but in this case might actually be good news.

What If Pfizer's and Moderna's Coronavirus Vaccine Results Are Delayed?

AstraZeneca

Johnson & Johnson

Sometimes it pays to know about the nuts and bolts of the clinical trial process.

Everything Investors Need to Know About Investigational New Drug Submissions

Beyond Meat

Workhorse Group

American Airlines

Apple

Tesla

Zoom Video

These seven stocks have outrun their valuations and are worth watching from the sidelines until a significant pullback takes their share prices back down to earth. The post 7 Overvalued Stocks Investors Should Sell This October appeared first on InvestorPlace.

7 Overvalued Stocks Investors Should Sell This October

Albertsons Companies

Ardagh Group

Berry Global Group

Brighthouse Financial

Brookfield Property REIT

Salesforce

Immunomedics

Livongo Health Inc

NortonLifeLock

NRG Energy

QuidelOrtho Corp

These are the stocks with the best value, fastest growth, and most momentum for October 2020.

Top Stocks for October 2020

Fastly

Focusing too much on common valuation metrics can be shortsighted with these high-flying stocks.

3 Stocks That Look Absurdly Overvalued but Really Aren't

Moderna Inc (NASDAQ: MRNA) CEO Stéphane Bancel scuttled hopes that a COVID-19 vaccine from the drugmaker would be available before the presidential election takes place in the United States in an interview with the Financial Times published Wednesday. What Happened: Bancel told FT that the Massachusetts-based company would not be in a position to seek emergency use authorization for the jab from the Food and Drug Administration before the end of November.

Moderna To Not Seek FDA COVID-19 Vaccine Approval Until After US Election

Gilead Sciences

5 Vaccine Stocks to Buy Now

CureVac B.V

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals stock rose on positive data on its possible Covid-19 treatment, while shares of Moderna and CureVac stock rose as their possible Covid-19 vaccines made advances. The post Covid Report: Regeneron, Moderna, CureVac Up As Possible Coronavirus Cures Advance appeared first on Investor's Business Daily.

Covid Report: Regeneron, Moderna, CureVac Up As Possible Coronavirus Cures Advance

As 2020 begins to wind down, some COVID-19 stocks are almost at the end of the journey for developing a treatment and vaccine.

2 Big Positive Developments in the COVID-19 Vaccine Race

The roaring 2020s started with a red-hot market that melted down into a 35% sell-off in less than a month.

4 Companies in Late-Stage Coronavirus Vaccine Testing: Will Big Pharma Win the Race?

Moderna MRNA, -0.04% rose 4% in early premarket trade as it said late Tuesday that early-stage data suggests its COVID-19 vaccine can generate neutralizing antibodies in older and elderly adults at levels comparable to those in younger adults. The study was published in The New England Journal of Medicine.

Moderna climbs after saying COVID-19 vaccine generates antibodies in older adults

Lonza said Tuesday the plants it's building to manufacture Moderna Inc’s (NASDAQ: MRNA) COVID-19 vaccine in the United States and Switzerland will be ready this year, Reuters reported. What Happened: The Switzerland-based integrated healthcare solutions firm is building new production facilities in Portsmouth, New Hampshire, which will begin operations in November, according to Reuters.

Moderna COVID-19 Vaccine Partner Lonza Certain Of Starting Commercial Production This Year

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces publication of interim results from older adult age cohorts in Phase 1 study of its mRNA vaccine in NEJM.

Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

Inovio Pharmaceuticals

Why Investors Should Buy Moderna Instead Of Inovio

BioNTech SE

Both of these biotechs have performed well this year, but should investors purchase shares of either?

These 2 Biotech Stocks Are Winning the Coronavirus Vaccine Race

Moderna has emerged as a strong competitor in the race for a coronavirus vaccine. But Moderna stock remains on a wild ride in 2020 as the need for a Covid-19 vaccine grows.

Moderna Is Among Coronavirus Vaccine Leaders — But Is MRNA Stock A Buy?

Moderna (MRNA) stock's two-month correction may have come to an end, setting the stage for higher prices.

Moderna (MRNA) Back In Rally Mode

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to present at the Chardan Virtual 4th Annual Genetic Medicines Conference.

Moderna to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference

These players -- a biotech and a pharma giant -- are leading in terms of timeline, data, and the logistics of bringing a vaccine to the masses.

The 2 Coronavirus Vaccine Stocks I'd Buy Right Now

The biotech's COVID-19 vaccine could be merely the tip of the iceberg.

Here's the Bigger Story About Moderna That You Might Be Missing

Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) has impressed Wall Street analysts with its comprehensive approach and forward thinking.
 The Moderna Analyst:  Oppenheimer analyst Hartaj Singh maintained an Outperform rating and $108 price target.

Moderna Will Start To Outrun Coronavirus Competition In 2021, Analyst Says

Our indicative theme of Coronavirus Vaccine stocks - which includes a diverse set of U.S. based pharma and biotech stocks that are working on Covid-19 vaccines - is up by over 670% year-to-date, on an equally weighted basis, compared to the S&P 500 which has gained just about 3% over the same period

Moderna, Pfizer: Are Covid Vaccine Stocks A Buy As Markets Await Efficacy Data?

Both biotechs could be winners in fighting COVID-19, but which is more likely to be the bigger winner for investors?

Better Coronavirus Stock: Gilead Sciences vs. Moderna

Moderna Inc (NASDAQ: MRNA) is one of the frontrunners in a crowded race to develop a  vaccine  against the novel coronavirus. Despite Moderna's strong positioning, an analyst at SVB Leerink said he harbors some concerns over the company's vaccine program.

Moderna Analyst On 4 Coronavirus Vaccine Program Risks

Biogen

Bio-Rad Laboratories

CVS Health

Insulet

Perrigo

These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2020.

News for Moderna Stock (MRNA)